Clinical trial
Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder: Double-Blind, Placebo-Controlled, Randomized Clinical Study of a Novel Approach
NCT05363982 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder: Double-Blind, Placebo-Controlled, Randomized Clinical Study of a Novel Approach
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 11, 2022
- Completion date
- October 31, 2024
- Enrollment
- 41 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.